Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.50 |
| ▸ | LCK | P06239 | 5/20 | 0.50 |
| ▸ | TEK | Q02763 | 5/20 | 0.50 |
| ▸ | SRC | P12931 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | ADK | P55263 | 6/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13020347 | 0.90 | KDR (0.56) | KDRLCKTEKSRCKDM4E | |
| SCHEMBL13020105 | 0.88 | KDR (0.54) | KDRLCKTEKSRCKDM4E | |
| SCHEMBL13020194 | 0.88 | KDR (0.54) | KDRLCKTEKSRCKDM4E | |
| SCHEMBL13020179 | 0.84 | KDR (0.50) | KDRLCKTEKSRCKDM4E | |
| SCHEMBL13020174 | 0.84 | SRC (0.50) | KDRLCKTEKSRCKDM4E | |
| SCHEMBL13020196 | 0.82 | HTT (0.67) | KDRLCKTEKSRCKDM4E | |
| SCHEMBL13020173 | 0.81 | KDM4E (0.63) | KDRLCKTEKSRCKDM4E | |
| SCHEMBL13020138 | 0.80 | LCK (0.61) | KDRLCKTEKSRCKDM4E | |
| SCHEMBL13840229 | 0.78 | LCK (0.56) | KDRLCKTEKSRCKDM4E | |
| SCHEMBL13020123 | 0.78 | LCK (0.58) | KDRLCKTEKSRCKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | KDR 4598/4885LCK 1980/4885TEK 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.